In contrast, a body of evidence indicated that BTG1 expression was negatively correlated with tumor invasion, lymph node metastasis, clinic stage, histological grade, pathological differentiation, or a low survival rate of patients with hepatocellular, thyroid, breast, or esophageal cancer (23–26). This evidence concerns the gene BTG1 and neoplasm.